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We report an investigation of gene dosage at 9p21.3 and mutations in BRAF and NRAS, as predictors of relapse and histo-
logical markers of poor melanoma prognosis. Formalin-ﬁxed primary melanomas from 74 relapsed and 42 nonrelapsed
patients were sequenced for common BRAF and NRAS mutations (N ¼ 71 results) and gene dosage at 9p21.3 including the
genes CDKN2A (which encodes CDKN2A and P14ARF), CDKN2B (CDKN2B), and MTAP was measured using multiplexed
ligation-dependant probe ampliﬁcation (MLPA), (N ¼ 75 results). BRAF/NRAS mutations were detected in 77% of relapsers
and 58% of nonrelapsers (Fisher’s exact P ¼ 0.17), and did not predict ulceration or mitotic rate. There was no relation-
ship between BRAF/NRAS mutations and gene dosage at 9p21.3. Reduced gene dosage at MTAP showed a borderline associ-
ation with BRAF mutation (P ¼ 0.04) and reduced gene dosage at the interferon gene cluster was borderline associated
with wild type NRAS (P ¼ 0.05). Reduced gene dosage in the CDKN2A regions coding for CDKN2A was associated with
an increased risk of relapse (P ¼ 0.03). Reduced gene dosage across 9p21.3 was associated with increased tumor thick-
ness, mitotic rate, and ulceration (P ¼ 0.02, 0.02, and 0.002, respectively), speciﬁcally in coding regions impacting on
CDKN2B and P14ARF and CDKN2A. Loss at MTAP (P ¼ 0.05) and the interferon gene cluster (P ¼ 0.03) on 9p21 was
also associated with tumor ulceration. There was no association between reduced gene dosage at 9p21.3 and subtype or
site of tumor. This study presents supportive evidence that CDKN2B, P14ARF, and CDKN2A may all play a tumor sup-
pressor role in melanoma progression. V V C 2010 Wiley-Liss, Inc.
INTRODUCTION
The AJCC staging system for melanoma uti-
lizes the Breslow thickness of primary melanoma,
the presence of ulceration, and staging by senti-
nel node biopsy to give the best estimate of prog-
nosis (Balch et al., 2001). Use of the staging
system is associated with a range of estimates of
outcome (Balch et al., 2001; Gimotty et al., 2005),
so that a signiﬁcant proportion of the variance in
survival remains unexplained. Therefore, it is im-
portant to seek molecular markers of metastatic
potential for use in clinical practice. In recent
years, progress has taken place in understanding
the somatic events that occur in melanoma pri-
mary tumors. However, there is comparatively lit-
tle known of the correlation between these
events and outcome, and it is therefore important
to increase our understanding of the carcinoge-
netic process so that logical approaches to treat-
ment can be developed.
A number of signal transduction and cell cycle
regulatory pathways have been implicated in the
etiology and progression of melanoma, including
the retinoblastoma (RB1) and p44/42 mitogen-
activated protein kinase (MAPK) pathways. A
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V V C 2010 Wiley-Liss, Inc.key region is 9p21.3, which contains the CDKN2A
and CDKN2B genes. These genes encode three
separate tumor suppressor proteins. CDKN2A enc-
odes both CDKN2A and, using a separate ﬁrst
exon and alternate reading frame, P14ARF.
Although both transcripts use exons 2 and 3 of
CDKN2A, the CDKN2A and P14ARF proteins
share no homology at the amino acid level and
have distinct tumor suppressor functions in the
RB1 and TP53 pathways; CDKN2B encodes
CDKN2B, which has its own open reading frame
(Sharpless and DePinho, 1999; Weber et al.,
1999). The CDKN2A protein controls passage
through the G1 checkpoint of the cell cycle by
inhibiting the phosphorylation of the RB1 protein
(Roussel, 1999) and of the three tumor suppres-
sors at this locus is the one longest recognized to
have a signiﬁcant role in melanoma. It is known
to play a key role in normal melanocyte senes-
cence (Ha et al., 2008). The P14ARF protein acts
on the TP53 cell cycle control pathway by inter-
action with the human double minute (HDM2)
protein to stabilize TP53 and allow cell cycle
arrest at the G1/G2 phase (Weber et al., 1999).
CDKN2A was identiﬁed ﬁrst as a tumor suppres-
sor gene commonly deleted/mutated in tumor
cell lines (Kamb et al., 1994a) and subsequently
its role as a high-risk susceptibility gene in mela-
noma families was elucidated (Kamb et al.,
1994b). Germline mutations have been identiﬁed
in  20% of tested melanoma families (Goldstein
and Tucker, 2001; Bishop et al., 2002). Some
mutations impact on CDKN2A protein alone,
some on P14ARF, and some on both proteins.
Most melanoma cell lines show deletion/muta-
tion of CDKN2A (Flores et al., 1996; Walker et al.,
1998). The majority of primary tumors have allelic
loss at microsatellite markers mapping to the
CDKN2A locus, indicating that deletions are the
principal genetic event in vivo (Flores et al., 1996;
Rodolfo et al., 2004). More recent reports showed
biallelic deletion in  45% of melanoma metasta-
ses, supporting the role of this locus in melanoma
progression (Grafstrom et al., 2005) and we have
shown that epigenetic silencing of P14ARF is also
common in metastatic disease (Freedberg et al.,
2008). There are few data from primary tumors on
the role of deletion at the locus on outcome (Koy-
nova et al., 2007) and none on the effect of dele-
tion across the larger region, which we have
addressed using Multiplex ligation-dependent
probe ampliﬁcation (MLPA) (Nygren et al., 2005)
rather than by studying the small intragenic
regions previously reported.
More recently there has been some suggestion
that CDKN2B may also have tumor suppressor
functions in melanoma. Krimpenfort et al. (2007)
showed that mice null for CDKN2B, CDKN2A,
and P14ARF were more tumor prone than
CDKN2A/P14ARF null mice and developed a
predominance of skin tumors (Krimpenfort et al.,
2007). The authors suggested that CDKN2B
might act as critical ‘‘back up’’ tumor suppressor
in cells null for CDKN2A.
Activating mutations of the NRAS and BRAF
genes occur in  20 and 50% of malignant mela-
nomas respectively, and are almost always mutu-
ally exclusive (Omholt et al., 2003; Garnett and
Marais, 2004). BRAF and NRAS mutations have
also been found in benign nevi (Poynter et al.,
2006) and are therefore thought to be involved
early in melanoma carcinogenesis. In cultured
human melanocytes, mutant BRAF protein has
been shown to induce cell senescence by increas-
ing the expression of CDKN2A (Michaloglou
et al., 2005). It is postulated, therefore, that to
become an invasive melanoma, arrest of the cell
cycle caused by normal CDKN2A must subse-
quently be overcome by mutation or deletion of
CDKN2A or by alterations to other cell cycle reg-
ulators. Moreover, a recent in vitro study showed
that simultaneous knockdown of BRAF and
expression of CDKN2A in melanoma cells led to
potent growth inhibition and apoptosis, whereas
knockdown of BRAF or expression of CDKN2A
alone did not (Zhao et al., 2008). Studies of
BRAF mutated nevi using the senescence marker
SA-b-gal, however, revealed a marked mosaic
induction of CDKN2A, which the authors sug-
gested was indicative of a role for multiple tumor
suppressors in the prevention of BRAF oncogene-
sis (Michaloglou et al., 2005).
In this study, we have investigated the gene
dosage of multiple tumor suppressors at 9p21 in
formalin-ﬁxed, parafﬁn-embedded (FFPE) pri-
mary melanoma tumors. Furthermore, we have
investigated the relationship between reduced
gene dosage at the CDKN2A locus and BRAF/
NRAS mutations using tumors from patients who
have relapsed and from patients with similar
tumors who have not relapsed, to determine the
prognostic value of these events. The presence of
ulceration is an important prognostic factor for
melanoma even in stage III or metastatic disease
(Balch et al., 2001) and, therefore, we also assessed
the associations between CDKN2A deletion and
BRAF/NRAS mutation and ulceration. In other
series, mitotic rate has important prognostic
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fore, we also examined genetic markers in relation
to mitotic rate. CDKN2A is a cyclin D kinase
(CDK) inhibitor and therefore loss of CDKN2A
would likely be related to increased mitotic rate.
The methylthioadenosine phosphorylase (MTAP)
gene is also located at 9p. It has been suggested
that loss of expression of the gene has prognostic
implications for melanoma (Behrmann et al., 2003)
and codeletion of MTAP with CDKN2A has been
investigated in a number of cancers (Chen et al.,
1996). There is evidence that loss of MTAP results
in an inhibition of STAT signalling pathways regu-
lated by interferon, so it is of interest that response
of melanoma patients to interferon used as an adju-
vant therapy for this cancer has been reported to
be related to MTAP status (Wild et al., 2007). We
were able in this study to look at deletion of
MTAP in primary melanomas.
MATERIALS AND METHODS
Patients
Ethical approval for this study was obtained
from the Multi-Regional Ethical Committee
(MREC) and from the patient information advi-
sory group (PIAG) and all living patients gave
informed written consent to the use of their
stored tissues for research. Melanoma cases had
all been diagnosed at least 3 years previously.
Recruitment was irrespective of family history.
Cases were then eligible as ‘‘relapsers’’ if relapse
occurred after 3 years or as ‘‘nonrelapsers’’ if they
were free of relapse. Participants had a tumor
thickness greater than 0.75 mm and were
recruited between May 2000 and January 2005.
Full details of the study were reported previously
(Beswick et al., 2008). There were 424 patients
eligible for the study, of which 66% (278) partici-
pated. The median Breslow thickness was 1.6
mm (range 0.8-20). From the 278 participating
patients, 116 (74 relapsers and 42 nonrelapsers)
had FFPE primary tumor samples that were
available for further sampling and DNA extrac-
tion. There was no selection of these blocks,
other than that we used blocks which could be
traced.
Histology
Sections from the primary tumors were exam-
ined (blind to relapse status) by one pathologist
according to protocol (AB). The following were
recorded: Breslow thickness, site of the primary
tumor, histological sub-type, presence of ulcera-
tion, and mitotic rate in three categories (0, 1 to
6 and more than 6 per mm
2).
DNA Extraction
DNA was extracted from 116 FFPE primary
melanoma tumors, sampled horizontally at the
advancing edge of the tumor, in the vertical
growth phase, using a 0.8 mm   2 mm core bi-
opsy needle and haematoxylin and eosin stained
slides as a guide. The intent was to choose tissue
representative of the deepest part of the tumor
but which was sufﬁciently surrounded by tumor
that the sample contained minimal normal stroma
and inﬂammatory cell inﬁltrate. Horizontal sec-
tions of cores were taken during development of
the methodology to ensure the technique allowed
minimal sampling of normal tissue as described
previously (Conway et al., 2009). DNA extraction
from cores was carried out using the QIAamp
DNA Mini kit (Qiagen, Sussex, UK) (Conway
et al., 2009).
Copy Number Analysis of Chromosome 9p21
Gene dosage ratios for 12 CDKN2A/CDKN2B
locus sites and 11 other 9p gene sites were deter-
mined using the 9p21 MLPA kit (P024 MRC-
Holland, Amsterdam, the Netherlands) (Schouten
et al., 2002). The genes included in this screen
were TEK, ELAV2, CDKN2B, CDKN2A, MTAP,
KIAA1354, INFW1, INFB1, MLLT3, and DOCK8
(Fig. 1A). The kit was used in accordance with
instructions for all experiments but in 1/4 vol-
umes of those recommended by the supplier,
based on previous optimization in our laboratory:
30–100 ng of extracted tumor DNA was dena-
tured and target gene probes were hybridized to
the target DNA prior to probe ligation in the
presence of ligase-65. The ligation products were
subject to polymerase chain reaction (PCR) ampli-
ﬁcation performed on a GeneAmp PCR System
9700 Thermal Cycler (Applied Biosystems,
Warrington, UK) with a hot-start PCR program.
MLPA fragments were visualized on an ABI
3130XL Automated DNA Sequencer with a 36 cm
capillary array, ABI POP-7 polymer, and GeneS-
can-ROX 500 size standards (Applied Biosystems).
Peak detection analysis has been automated using
ABI PRISM Genescan
V R Analysis software version
3.1 (Applied Biosystems) and GeneMarker soft-
ware (Softgenetics, State College, Pennsylvania,
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control (no DNA) sample and four normal control
samples (human genomic DNA with normal gene
dosage at 9p from four different individuals) were
included.
MLPA Data Analysis
Gene dosage analysis was automated using
the MLPA analysis program included with
GeneMarker software version 1.6 (Softgenetics,
Pennsylvania, USA) according to the manufac-
turer’s instructions. Data were normalized using
the ‘‘population normalization’’ mode (as recom-
mended by the MLPA kit manufacturers for anal-
ysis of tumor DNA). Peak heights were
normalized according to the median height of all
test and control peak heights of similar fragment
size. Normalized peak heights were then com-
pared to a synthetic control sample (average of
Figure 1. MLPA for analysis of gene dosage at chromosome 9p21.
A, a diagrammatical representation of the 9p21 region covered by
the P024A MLPA kit. Locations of probed genes are shown in green
and MLPA probes in orange with probe names outlined in bold.
Probe groupings used in data analysis are represented by orange bars
with black dots at top of the picture. B, gene dosage ratios for a rep-
resentative primary melanoma sample showing an almost total loss of
gene dosage (representing  80% loss) from MTAP exon 6 to
CDKN2B intron.
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samples with normal gene dosage at 9p) with
default analysis parameters to determine gene
dosage ratios where the median point within the
data set is considered to be 1, and a gene dosage
ratio for each probe region was calculated with
reference to the synthetic control (Fig. 1B). In
previous publications using MLPA on FFPE-
derived DNA, gene dosage cut-offs of 0.7 for loss
and 1.3 for gain have been used according to
manufacturer’s instructions (van Dijk et al., 2005;
Takata, 2008; Buffart et al., 2009) (and author
correspondence with MRC-Holland). In our anal-
ysis, gene dosage was treated as a continuous
variable to account for the effect of any possible
contaminating normal DNA.
Mutation Analyses
Gene fragments of hotspot mutation regions in
BRAF (exon 15) and NRAS (exon 2) were ampli-
ﬁed by PCR in separate reactions to screen for
common mutations found in melanomas. Stand-
ard PCR reactions were carried out using Ampli-
taq Gold DNA polymerase in 1  PCR buffer
(Applied Biosystems) according to manufacturer’s
instructions. Primers: BRAF exon 15 Forward:
50-TCA TAATGCTTGCTCTGATAGGA and
Reverse: 50-GGCCAAAAATTTAATCAGTGGA
(annealing temperature 59 C); and NRAS exon 2
Forward: 50-GGTGAAACCTGTTTGTTGGA
and Reverse: 50-TTCAGAACACAAAGATCATC
(55 C).
BRAF and NRAS PCR products were
sequenced in both directions using an ABI3100
Automated DNA Sequencer with a 36 cm capil-
lary array, ABI POP-7 polymer and ABI Prism
BigDye Terminator Cycle Sequencing Kit ver-
sion 1.1 (Applied Biosystems) according to the
manufacturer’s instructions. Sequence analysis
was carried out using CodonCode Aligner
sequencing software (CodonCode Corporation,
Dedham, MA, USA) and mutation detection was
based on BRAF and NRAS cDNA sequences
(Genbank accession nos. NM_004333 and
NM_00254, respectively).
CDKN2A Immunohistochemistry
A representative set of 17 tumors from the
MLPA data set were selected for immunohisto-
chemistry using antibodies to CDKN2A to evi-
dence the validity of the MLPA results. The
samples chosen consisted of four samples with
gene dosage ratios of  0.2 (80% gene dosage
loss) at the CDKN2A promoter, or coding regions
for CDKN2A; seven samples with gene dosage
ratios  0.5 (50% gene dosage loss) at the
CDKN2A promoter, coding regions for CDKN2A
or intronic regions upstream of the promoter; and
six samples with gene dosage ratios between 0.7
and 1.3 (normal gene dosage). Positive and nega-
tive controls for kit and antibody performance
were included. The positive control was a paraf-
ﬁn-embedded section of bladder carcinoma with
high CDKN2A expression determined by West-
ern blot analysis. The negative control was a sec-
tion from the same bladder tumor without the
addition of primary antibody.
Sections (5 lm) were cut and ﬁxed on Super-
frost plus glass slides before dewaxing and rehy-
dration. Expression of CDKN2A was examined
using a CDKN2A monoclonal antibody (1:1500
for 1 hr; Ab-7; Labvision, Freemont, CA, USA)
and the catalyzed signal ampliﬁcation system
(CSA system; DakoCytomation, Cambridgeshire,
UK) according to the manufacturer’s instructions.
Endogenous biotin or biotin-binding proteins
were blocked using the Avidin Biotin blocking
kit (Vector Laboratories, Peterborough, UK)
according to manufacturer’s instructions and en-
dogenous peroxidase activity was blocked using
3% hydrogen peroxide in water for 5 min (CSA
system). Sections were counterstained with hema-
toxylin, dehydrated and mounted in Depex
mounting medium (VWR International, Leices-
tershire, UK). Expression of CDKN2A was exam-
ined by light microscopy and scored in tumors as
absent (0), expressed (1) or highly expressed (2).
Statistical Methods
Gene dosage was treated as a continuous vari-
able in the analysis (Fig. 1). To investigate the
effect of dosage in relation to each of the tran-
scripts at 9p21, ﬁve separate probe groups were
created. Probe groups contained all probes located
within the coding exons and promoter for each
transcript. The probe groups were: (1) CDKN2B
(probes: CDKN2B promoter and exon 1), (2)
regions coding for P14ARF (probes: CDKN2A
CpG island, CDKN2A 1b promoter and exons 1b,
2, and 3), (3) CDKN2A (probes: CDKN2A 1a pro-
moter and exons 1a, 2, and 3), (4) MTAP (probes:
MTAP exons 1, 6, and 7), and (5) the interferon
gene cluster (probes: KIAA1354 [between IFNA5
and IFNA6], INFW1, and INFB1). A ‘‘CDKN2A’’
group containing all CDKN2A probes was created
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CDKN2A locus (probes: CDKN2A CpG island,
CDKN2A 1b promoter, exon 1b, CDKN2A introns 1
and 2, CDKN2A 1a promoter plus exons 1a, 2 and
3). To investigate the effect of loss across the
whole 9p21.3 region, an overall 9p21.3 group
deﬁned by all of the probes in the region was also
considered. Median gene dosage ratio was used to
represent the overall gene dosage ratio of the
region where there was more than one probe
within the region.
A rolling average heatmap was used to repre-
sent graphically the overall gene loss. The rolling
average of the gene dosage was calculated as the
average gene dosage ratio of the probe itself and
adjacent probes. The Wilcoxon two-sample rank
test using normal approximation was performed
to assess the difference between gene dosage ra-
tio by relapse status (relapse versus no relapse),
ulceration status (yes versus no), tumor site
(head/neck/foot/hand versus others) and BRAF
and NRAS mutation status. The Kruskal Wallis
test was applied to assess the difference between
tumor histological sub-type (superﬁcial spreading
versus nodular) and mitotic rate per mm
2
(grouped as 0, 1–6, >6). Spearman correlations (r)
were used to assess association between gene
dosage ratio and Breslow thickness. Fisher’s exact
test was used to assess the association between
BRAF/NRAS mutation and relapse status, mitotic
rate and ulceration. These analyses were carried
out using the SAS/STAT statistical software ver-
sion 9.1 for PC (Copyright, SAS Institute Inc.
Cary, NC, USA). The rolling average heatmap
was illustrated using heatmap.2<gplots> function
in R version 2.9.0 (Vienna, Austria).
RESULTS
Samples
In total, 116 primary tumor blocks from 116
patients (74 relapsers and 42 non-relapsers) were
sampled for DNA extraction and molecular analy-
sis. The median DNA concentration was 28 ng/ll
(range 4–493 ng/ll) with elution volumes of 25 ll
resulting in a median total yield of 0.7 lg/tumor.
The median tumor block age was 11 years (range
5-36 years). From the 116 tumor blocks sampled,
50 produced DNA of sufﬁcient quality for both
MLPA and BRAF/NRAS analysis, 25 produced
results for MLPA only, 21 produced results for
BRAF/NRAS only and 20 did not produce any
results. Therefore, the success rate for MLPA
was 65% (75/116) and that for BRAF/NRAS was
61% (71/116). There was no signiﬁcant difference
in the distribution of block age between samples
with a MLPA result (median 10 years, range
5–36) and those that failed (median 12 years,
range 5–24), P ¼ 0.3 (Wilcoxon rank test). The
strongest predictor of assay success was DNA
quantity. Failure was much more likely to occur
in assays with <100 ng DNA input (44% fail rate
at <100 ng DNA compared to 17% fail rate at
>100 ng DNA), according to the DNA quantity
control peaks within each MLPA assay.
Gene Dosage at 9p21
Gene dosage at 9p21 was successfully meas-
ured in 75 vertical growth phase primary melano-
mas (48 relapsers and 27 non-relapsers) using
MLPA. Gene dosage ratios for 12 CDKN2A/
CDKN2B locus sites and 11 other 9p gene sites
were determined. Reduced gene dosage was
more frequent in relapsers (Fig. 2). It can be
seen that although loss of gene dosage occurred
across 9p (especially in relapsers) the most com-
mon region of loss was between CDKN2A exon
1a (coding for CDKN2A) and MTAP. The me-
dian gene dosage at eight key regions across 9p,
and their association with relapse or histological
indicators of poor prognosis are presented in Ta-
ble 1. Relapse was associated with loss at 9p21.3
overall (P ¼ 0.04) and loss in regions coding for
CDKN2A (one sided P ¼ 0.03, two sided P ¼
0.05), and (borderline) associated with loss any-
where in the CDKN2A region (from CDKN2A
CpG island probe to CDKN2A exon 3 probe)
(one-sided P ¼ 0.05, two-sided P ¼ 0.1) but not
elsewhere across 9p.
Loss anywhere in the CDKN2A region was
associated with ulceration (P ¼ 0.002). However,
ulceration of the tumor was most signiﬁcantly
associated with reduced gene dosage at CDKN2B
(one sided test P ¼ 0.006, two sided P ¼ 0.01)
and regions coding for P14ARF (one sided P ¼
0.002, two sided P ¼ 0.004). There was some evi-
dence of an association between ulceration and
reduced gene dosage at CDKN2A coding for
CDKN2A, MTAP, and the interferon gene cluster
(Table 1).
Relative loss across the region was associated
with increasing tumor thickness (Fig. 3). Spear-
man correlation coefﬁcients are given for thick-
ness and reduced gene dosage across the
CDKN2A region (Table 1). The most signiﬁcant
correlation was with reduced gene dosage at
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was some association across 9p21.3 (P ¼ 0.02).
To summarize, at 9p increasing thickness corre-
lated with loss impacting on the coding regions of
CDKN2B, CDKN2A, but not with loss in
intronic regions of CDKN2A, MTAP or the inter-
feron gene cluster. Increased mitotic rate was
associated with reduced gene dosage across
CDKN2A and especially in regions coding for
P14ARF and CDKN2A (one sided P ¼ 0.0006
and 0.004, respectively). There was no association
between reduced gene dosage at 9p and tumor
site or melanoma subtype (Table 1).
There was no signiﬁcant association between
BRAF and NRAS mutation status and reduced
gene dosage in the CDKN2A/CDKN2B regions
with the Wilcoxon Two-Sample test, but there
was a trend toward an association between the
presence of BRAF mutations and loss at regions
coding for CDKN2A (one sided P ¼ 0.06, two
sided P ¼ 0.12). The absence of BRAF mutation
was associated with reduced gene dosage at
MTAP (one sided P ¼ 0.04, two sided P ¼ 0.09)
and the absence of an NRAS mutation was (bor-
derline) associated with reduced gene dosage at
the interferon gene cluster (one sided P ¼ 0.05,
two sided P ¼ 0.10).
BRAF and NRAS Mutations
Seventy-one tumors were successfully assayed
for common mutations activating the MAPK
pathway in melanoma, i.e., BRAF exon 15 and
NRAS exon 2 mutations. Seventy-seven percent
Figure 2. Heatmap of gene dosage at chromosome region 9p21 by relapse status. Gene dosage ratios
are shown for tumors from 45 relapsed patients (above) compared with tumors from 27 patients who
had not relapsed. Blue coloration indicates reduced gene dosage, red coloration indicates increased
gene dosage.
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with 58% of nonrelapsers (Fisher’s exact P ¼
0.17). There was no association between NRAS/
BRAF mutation and mitotic rate or presence of
ulceration (Fisher’s exact P ¼ 0.42), nor with
thickness (P ¼ 0.97). 71% of non-acral tumors
had a mutation compared with 50% of acral
tumors (P ¼ 0.25). There were a slightly higher
proportion of superﬁcial spreading tumors than
nodular tumors with a mutation (78 and 60%,
respectively).
Expression of CDKN2A in Primary Melanomas
High speciﬁcity of staining was achieved in the
control sections, where in the absence of primary
antibody only haematoxylin staining is observed
(Fig. 4A). In the presence of primary antibody,
intense nuclear and cytoplasmic staining was
observed for CDKN2A in some samples (Fig.
4B). In the 17 melanomas tested, the staining
pattern varied from absent to strong cytoplasmic
and nuclear staining. The level of positive
expression of CDKN2A was associated with
MLPA results of gene dosage in CDKN2A coding
regions for CDKN2A in the majority of tumors
(13/17) (Table 2). In the four samples with 80%
gene dosage loss, there was a complete absence
of CDKN2A expression in the region sampled for
DNA extraction (Fig. 4C). In the seven samples
with 50% gene dosage loss of the intronic, pro-
moter or coding regions of CDKN2A, there was
Figure 3. Heatmap of gene dosage at chromosome region 9p21 by Breslow thickness. Gene dosage
ratios are shown for 18 tumors with Breslow thickness <2 mm (above), 30 tumors with Breslow thick-
ness 2–4 mm (middle) and 27 tumors of thickness >4 mm. Blue coloration indicates reduced gene dos-
age, red coloration indicates increased gene dosage.
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samples, while the remaining three showed
strong CDKN2A expression. In the six samples
that showed normal gene dosage at CDKN2A 5/6
showed strong to moderate CDKN2A expression
(Fig. 4D) and one showed no expression of
CDKN2A.
DISCUSSION
We have examined the role of BRAF and
NRAS mutations and reduced gene dosage at 9p
in melanoma relapse. The study was carried out
using formalin-ﬁxed parafﬁn-embedded (FFPE)
tumors because of the difﬁculties in accessing
cryopreserved primary tumors; melanomas are
generally too small to allow cryopreservation. In
the study, 65% of tumors sampled yielded
enough DNA for MLPA screening and 61%
were successfully sequenced for BRAF/NRAS
mutations.
Figure 4. Immunohistochemistry of CDKN2A in primary tumors.
(A) Bladder tumor control minus primary antibody. Some nonspeciﬁc
stromal staining is visible in the stroma. (B) Strong speciﬁc cytoplasmic
and nuclear staining in a bladder positive control in presence of pri-
mary antibody. (C) Results from representative tumors show very low
cytoplasmic staining of CDKN2A from a tumor with a large homozy-
gous deletion of CDKN2A. (D) Strong nuclear and cytoplasmic staining
of CDKN2A and unstained normal stromal cells from a tumor which
retained 2 copies of CDKN2A. Scale bar ¼ 25 lm.
TABLE 2. Summary of CDKN2A Protein Expression Results
Determined by Immunohistochemistry
Sample Relapse CDKN2A gene dosage
CDKN2A
expression
1N   80% loss intron/promoter 0
2Y   80% loss whole gene 0
3Y   80% loss whole gene 0
4Y   80% loss whole gene 0
5 Y 50% loss promoter 2
6 N 50% loss intron 0
7 N 50% loss intron/gene 1
8 N 50% loss gene 2
9 N 50% loss intron 2
10 Y 50% loss intron 0
11 Y 50% loss intron/promoter 0
12 Y Normal 2
13 N Normal 2
14 N Normal 0
15 N Normal 2
16 Y Normal 2
17 Y Normal 1
Intensity of staining was scored as absent (0), expressed (1), or highly
expressed (2). CDKN2A gene dosage determined by MLPA analysis is
shown for each tumor sample.
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ing failure rate was higher in samples with lower
DNA quantity indicates a potential for bias to-
ward successful sampling of thicker, poorer prog-
nosis tumors. However, failure rate was
comparable in both relapse and nonrelapse
groups, and over 40% low DNA input samples
gave reliable results.
We found deletion (reduced gene dosage) at
the CDKN2A locus to be common in primary mel-
anoma. This is consistent with previous studies
which have shown that deletion at CDKN2A
appears to be the major mechanism of CDKN2A
inactivation in primary melanomas (Funk et al.,
1998; Fujimoto et al., 1999; Rizos et al., 1999;
Cachia et al., 2000; Straume et al., 2002; Zhang
and Rosdahl, 2004). We did not screen for muta-
tions as previous studies have consistently shown
small sequence alterations to be uncommon
(Ruiz et al., 1998; Cachia et al., 2000). Epigenetic
silencing of CDKN2A by methylation (Gonzalgo
et al., 1997; von Eggeling et al., 1999; Straume
et al., 2002) could not be investigated in this
study due to constraints on DNA availability
from small tumors. However, protein expression
of CDKN2A by immunohistochemistry correlated
well with gene dosage ratios as determined by
MLPA in the majority of tumors investigated,
and is consistent with the view that deletion
remains the dominant method of CDKN2A silenc-
ing in primary melanoma.
Reduced gene dosage impacting on CDKN2A
was predictive of relapse. Loss impacting on
P14ARF was, however, more strongly associated
with poor prognostic factors such as increased
Breslow thickness but particularly with mitotic
rate and ulceration, than was loss impacting on
CDKN2A. This suggests that loss of P14ARF has
a key role in the progression of melanoma. This
is consistent with our recent work in metastases,
which demonstrated the loss of P14ARF by
methylation or deletion to be common in metas-
tases (Freedberg et al., 2008). This is the ﬁrst
study to report on loss across the critical region of
9p in primary melanoma, although loss of
CDKN2A coding for CDKN2A has been sug-
gested by others to be associated with poorer
prognosis (Cachia et al., 2000; Grafstrom et al.,
2005) and loss of CDKN2A expression immuno-
histochemically correlates with histological inva-
sion (Talve et al., 1997; Pavey et al., 2002).
Furthermore, the study suggests that within verti-
cal growth phase melanoma, although loss
impacting on CDKN2A was most frequent, wider
deletions involving P14ARF and even CDKN2B
were associated with poorer histological prognos-
tic factors. Loss of CDKN2A is a common occur-
rence even in early melanoma (Tran et al., 2002).
It is perhaps not surprising then, that further loss
of the second melanoma tumor suppressor gene
at 9p (P14ARF) impacts on outcome. There is in
vitro evidence for a tumor suppressive role for
CDKN2B in melanoma (Ha et al., 2008; Peters,
2008; Schlegel et al., 2009). That reduced gene
dosage impacting on CDKN2B also correlates
with poor histological characteristics is supportive
of the view that it too may play a role in tumor
suppression in melanocytes.
One previous study has suggested that BRAF
and NRAS mutations are less common in primary
tumors with allelic loss on 9p (Kumar et al.,
2003), and other studies using microsatellite
markers located in the CDKN2A locus showed
both BRAF/NRAS mutation and LOH at
CDKN2A (Rodolfo et al., 2004). We showed no
signiﬁcant association between the presence of ei-
ther BRAF or NRAS mutations and reduced gene
dosage at 9p. Mutations in the BRAF/NRAS
genes were not signiﬁcantly associated with ulcer-
ation or Breslow thickness in these tumors. These
observations are consistent with the view that
these mutations are an early event in melanoma,
required for initiation but not involved in pro-
gression (Platz et al., 2008), although there is one
study which suggested that BRAF and NRAS
mutations are more frequent in cells of the verti-
cal growth phase of a melanoma than in the radial
growth phase suggesting a selection for cells con-
taining the mutations (Greene et al., 2009). Cer-
tainly, BRAF or NRAS mutations present in the
primary tumor were found in the majority of asso-
ciated metastases in another study (Edlundh-
Rose et al., 2006). It is likely that secondary
events are necessary for metastatic progression in
addition to mutations in either BRAF or NRAS,
but this could occur through alteration of other
tumor suppressor genes or oncogenes not investi-
gated here, such as CDK4, PTEN, and TP53,a s
well as CDKN2A. As only melanomas with wild-
type BRAF have ampliﬁed CDK4 and cyclin D1
genes, the CDKN2A-CDK4/6-cyclin D pathway
is viewed as linearly downstream of BRAF (Zhao
et al., 2008). Inhibition of mutated BRAF using
new speciﬁc BRAF inhibitors is reported in 2009
(ASCO) to be effective so that whether BRAF is
a prognostic marker or not, BRAF driven MAPK
pathway activation clearly drives tumor growth in
melanoma tumors.
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recently been identiﬁed at 9p21.3 (Pasmant et al.,
2007). The ﬁrst exon of ANRIL is located in the
CDKN2A P14ARF promoter, and the gene over-
laps CDKN2B. There is evidence that ANRIL
may inﬂuence transcription of the CDKN2A and
CDKN2B genes (Jarinova et al., 2009; Liu et al.,
2009). The frequency of deletion of ANRIL in
primary melanoma tumors could not be investi-
gated in this study as the MLPA assay used does
not include probes speciﬁc for the ANRIL gene.
Deletion of MTAP is of interest as evidence for
reduced expression in poor prognostic tumors has
been reported before (Behrmann et al., 2003) and
there is some evidence that loss may moderate
response to interferon therapy (Wild et al., 2007).
In this study, however, we showed no evidence
for a role for MTAP in melanoma prognosis. We
did see an association between reduced gene dos-
age at MTAP and the absence of a BRAF muta-
tion, although the signiﬁcance of this observation
remains to be established.
In conclusion, we have identiﬁed a high fre-
quency of deletion in the CDKN2A gene in pri-
mary melanoma tumors, which supports previous
evidence that gene deletion is the major mode of
inactivation of CDKN2A and bypass of cell cycle
control required for proliferation and progression
to metastatic disease in malignant melanoma.
Reduced gene dosage at 9p (but not BRAF or
NRAS mutation) was associated with histological
features predictive of a poorer prognosis. The
study also suggests that loss of P14ARF has an
additional role in melanoma relapse and possibly
also a role for CDKN2B coded by CDKN2B.
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